Sign Out
Pharmacology: Pharmacodynamics: HEXBIO is a Microbial Cell Preparation (MCP) containing a unique formulation of six strain-specific microorganism (6) (Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC® 02129, and Bifidobacterium longum BCMC® 02120). These MCP-6 are a ubiquitous component of the normal gastrointestinal microbiota and do not have any pathogenic potential. Upon exposure to bile salt in the duodenum of the small intestine, MCP-6 are stimulated to produce Bile Salt Hydrolase (BSH) enzyme. HEXBIO work via their BSH activities, converting bile salts into primary bile acids. Primary bile acids play a fundamental role in increasing water secretion into the colon, thus stimulating gut motility. These MCP-6 also have inherent antibacterial and anti-inflammatory properties, inhibiting the growth of pathogenic bacteria and viruses, resulting in increased immunity. Coupled with their high gastrointestinal acid and bile tolerance, BSH activity and enhanced defence mechanism in the gastrointestinal tract, the specific Lactobacillus spp. and Bifidobacterium spp. strains of HEXBIO can lower the pH level of the colon (optimum acidic environment), enhance peristalsis, reduce colonic transit time, and contribute to the overall recovery and restoration of balance of the intestinal microbiota.
Pharmacokinetics: No signs of liver toxicity has been reported with the administration of HEXBIO MCP Granule. This product has a fast onset of action which improves symptoms shortly after consumption. All the MCP-6 in HEXBIO have been proven to be gastric acid resistant and bile salt resistant, thus able to survive via intestinal tract transit. This was demonstrated in a human clinical trial whereby a significantly increased strains of Bifidobacterium spp. and Lactobacillus spp. were detected in the faecal samples of subjects given HEXBIO compared to placebo group.
